Celaid Therapeutics and AGC Ink Research Pact on iPSC-HSPC Expansion and Evaluation
Celaid Therapeutics has partnered with AGC Inc. to advance scalable expansion of iPS cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs) by combining their respective stem cell technologies.
Global Pharma | 29/08/2025 | By Mrinmoy Dey | 115
Pacific Software Acquires 107 Canada from PurMinds
Pacific Software Inc. has acquired 10763942 Canada Inc. (107 Canada) and its PurMinds asset portfolio, strengthening its position in clinical-stage neuromedicine with a pipeline targeting neurological and psychiatric disorders.
Global Pharma | 27/08/2025 | By Mrinmoy Dey | 168
Clyra Medical Technologies Appoints David Zansitis as Vice President of Clinical Affairs
In this new role, David Zansitis will provide strategic clinical leadership, partnering with Clyra’s Chief Medical Officer to expand the company’s clinical roadmap.
Global Pharma | 27/08/2025 | By Dineshwori | 171
AbbVie to Acquire Gilgamesh's Psychedelic Antidepressant Bretisilocin in USD 1.2 Billion Deal
AbbVie has announced a USD 1.2 billion deal to acquire Gilgamesh Pharmaceuticals’ lead candidate bretisilocin, a next-generation psychedelic compound in clinical development for treating moderate-to-severe major depressive disorder.
Global Pharma | 26/08/2025 | By Mrinmoy Dey | 227
Scenic Biotech Partners with Alnylam to Advance RNAi Therapeutics Using Cell-Seq Platform
This collaboration represents Scenic Biotech’s third Cell-Seq collaboration with major US biotech and pharmaceutical companies, following ongoing multi-year agreements with Genentech and Bristol Myers Squibb. <br />
Global Pharma | 26/08/2025 | By Dineshwori | 304
Er-Kim Partners with CNX Therapeutics to Distribute Oncology Products Across CEE and Turkey
Istanbul-based Er-Kim, an international pharmaceutical company specialising in the commercialisation of novel therapies, has entered into a distribution agreement with UK-based CNX Therapeutics to supply selected oncology products across Central and Eastern Europe (CEE) and Turkey.
Global Pharma | 26/08/2025 | By Dineshwori | 386
Malaysia, Singapore Partner to Launch Medical Device Regulatory Reliance Pilot
The Medical Device Authority (MDA) of Malaysia and the Health Sciences Authority (HSA) of Singapore have signed a Memorandum of Understanding (MOU) to deepen regulatory cooperation and officially launched a 6-month pilot of the Medical Device Regulatory Reliance Programme.
Global Pharma | 26/08/2025 | By Dineshwori | 317
CuraTeQ Biologics Receives UK MHRA Approval for Trastuzumab Biosimilar Dazublys
CuraTeQ Biologics, a wholly owned step-down subsidiary of Aurobindo Pharma, has obtained marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its trastuzumab biosimilar, Dazublys.
Global Pharma | 26/08/2025 | By Dineshwori | 616
MannKind to Acquire scPharmaceuticals, Expanding into Cardiorenal Medicine
MannKind’s acquisition of scPharmaceuticals is expected to be completed in the fourth quarter of 2025.
Global Pharma | 25/08/2025 | By Dineshwori | 270
GSK Enters Oncology in India with Launch of Jemperli and Zejula for Gynaecological Cancers
GSK has launched its much-awaited advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in India, reinforcing its commitment to addressing the unmet need for gynaecological cancers in the country.
Global Pharma | 25/08/2025 | By Dineshwori | 377
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy